A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 599, doi. 10.1007/s00280-020-04229-3

By:

• Collier, Katharine A.;
• Valencia, Hugo;
• Newton, Herbert;
• Hade, Erinn M.;
• Sborov, Douglas W.;
• Cavaliere, Robert;
• Poi, Ming;
• Phelps, Mitch A.;
• Liva, Sophia G.;
• Coss, Christopher C.;
• Wang, Jiang;
• Khountham, Soun;
• Monk, Paul;
• Shapiro, Charles L.;
• Piekarz, Richard;
• Hofmeister, Craig C.;
• Welling, D. Bradley;
• Mortazavi, Amir

Publication type:

Article